ArticleMolecular diversity2026
Exploring Lamiaceae diterpenoids as potential multitarget therapeutics for leishmaniasis and chagas disease.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Molecular modeling design of antitrypanosomal pyrazolone derivatives targeting Chagas disease: QSAR, docking, molecular dynamics and free energy calculations.Journal of molecular modeling · 2026Article
- Biological Effects of Novel Synthetic Guanidine Derivatives TargetingMolecules (Basel, Switzerland) · 2026Article
- Trypanocidal Activity of Dual Redox-Active Quinones:Pathogens (Basel, Switzerland) · 2025Article
- Article
- Plant-based secondary metabolites as natural remedies: a comprehensive review on terpenes and their therapeutic applications.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Neglected tropical diseases such as Leishmaniasis and Chagas disease remain critical public health challenges. This study applied ligand-based virtual screening to a dataset of 4,150 secondary metabolites from the Lamiaceae family, aiming to identify multitarget molecules against four Leishmania species (L. infantum, L. donovani, L. amazonensis, and L. braziliensis) and Trypanosoma cruzi forms. Random forest models exhibited high accuracy (over 72%), leading to the identification of 82 molecules with potential multitarget activity across five of six predictive models. Nineteen prioritized molecules were subjected to molecular docking simulations targeting key enzymes-including sterol 14-alpha demethylase, glucose-6-phosphate dehydrogenase, dihydroorotate dehydrogenase, nucleoside diphosphate kinase, tryparedoxin peroxidase, and cruzain-with compounds 12, 18, and 19 exhibiting a high binding affinity across multiple targets. In vitro assays confirmed the predicted activity of selected molecules (3, 4, and 5) against Leishmania and T. cruzi. Importantly, these molecules represent novel findings, with antileishmanial or antitrypanosomal activities that have not been previously reported. The results highlight their potential as multitarget therapeutic candidates for neglected tropical diseases, paving the way for further biological evaluation and development.
Indexed as
Identifiers
40287545What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.